Will you recommend abemaciclib in combination with standard adjuvant endocrine therapy in patients with high risk hormone receptor positive, HER2- early breast cancer?
With the recent announcement that the phase 3 MonarchE trial met its primary endpoint.
I agree with the caution to avoid "practicing by p...